Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors
August 19 2020 - 9:00AM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the
appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President,
Clinical Data Analytics at Anthem, to its Board of Directors.
"We are delighted to welcome Liz to our Board of Directors as
her broad and deep background uniquely complements our existing
skills and experiences,” said Michael Clayman, MD, President
and Chief Executive Officer of Flexion Therapeutics. “We
are confident that she will provide important insights and extend
our thinking as we seek to execute our strategy, drive growth and
build long-term shareholder value."
Dr. Kwo has more than 15 years of experience specializing in
healthcare technology product development and commercialization,
marketing and sales, strategic partnerships, and post-merger
integration. As Staff Vice President of Clinical Data Analytics at
Anthem, she is responsible for creating an improved automated
patient and provider experience to drive down cost of care. Prior
to Anthem, Dr. Kwo co-founded and served as the CEO of InfiniteMD,
a telemedicine company connecting patients with physicians for
second opinions. She previously worked at Medtronic, American Well
and she also founded multiple venture-backed companies in
educational technology, digital healthcare and healthcare supplies.
Dr. Kwo earned a BA in Human Biology from Stanford University and
her MD from Harvard Medical School. She holds an MBA from Harvard
Business School and an MPH from Harvard TH Chan School of Public
Health. She completed her residency in Preventive Care at Harvard
Preventive Care and is Board Certified in Preventive Care and
Occupational Medicine.
"I am honored to join Flexion’s Board of Directors, excited by
the potential of ZILRETTA® and the pipeline candidates and eager to
help guide the company as it advances its critical mission of
discovering, developing and commercializing innovative treatments
for musculoskeletal conditions,” said Dr. Kwo.
Indication and Select Important Safety Information for
ZILRETTA (triamcinolone acetonide extended-release
injectable suspension)
Indication: ZILRETTA is indicated as an
intra-articular injection for the management of osteoarthritis pain
of the knee.
Limitation of Use: The efficacy and safety of repeat
administration of ZILRETTA have not been demonstrated.
Contraindication: ZILRETTA is
contraindicated in patients who are hypersensitive to triamcinolone
acetonide, corticosteroids or any components of the product.
Warnings and Precautions:
- Intra-articular Use Only: ZILRETTA has
not been evaluated and should not be administered by epidural,
intrathecal, intravenous, intraocular, intramuscular, intradermal,
or subcutaneous routes. ZILRETTA should not be considered safe for
epidural or intrathecal administration.
- Serious Neurologic Adverse Reactions with Epidural
and Intrathecal Administration: Serious neurologic
events have been reported following epidural or intrathecal
corticosteroid administration. Corticosteroids are not approved for
this use.
- Hypersensitivity reactions: Serious
reactions have been reported with triamcinolone acetonide
injection. Institute appropriate care if an anaphylactic reaction
occurs.
- Joint infection and damage: A marked
increase in joint pain, joint swelling, restricted motion, fever
and malaise may suggest septic arthritis. If this occurs, conduct
appropriate evaluation and if confirmed, institute appropriate
antimicrobial treatment.
Adverse Reactions: The most commonly
reported adverse reactions (incidence ≥1%) in clinical studies
included sinusitis, cough, and contusions.
Please
see ZilrettaLabel.com for
full Prescribing Information.
About ZILRETTA On October 6, 2017, ZILRETTA was
approved by the U.S. FDA as the first and only extended-release
intra-articular therapy for patients confronting
osteoarthritis-related knee pain. ZILRETTA employs proprietary
microsphere technology combining triamcinolone acetonide — a
commonly administered, short-acting corticosteroid — with a poly
lactic-co-glycolic acid (PLGA) matrix to provide extended pain
relief. The pivotal Phase 3 trial on which the approval of ZILRETTA
was based showed that ZILRETTA significantly reduced OA knee pain
for 12 weeks, with some people experiencing pain relief through
Week 16. Learn more at www.zilretta.com.
About Flexion Therapeutics Flexion
Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company
focused on the development and commercialization of novel, local
therapies for the treatment of patients with musculoskeletal
conditions, beginning with osteoarthritis, a type of degenerative
arthritis. The Company's core values are focus, ingenuity,
tenacity, transparency and fun.
Visit flexiontherapeutics.com.
Forward-Looking Statements This release
contains forward-looking statements that are based on the current
expectations and beliefs of Flexion. Statements in this press
release regarding matters that are not historical facts, including,
but not limited to, statements relating to the future of Flexion;
future contributions of Dr. Kwo and potential growth and
shareholder value creation, are forward looking statements. These
forward-looking statements are based on management’s expectations
and assumptions as of the date of this press release and are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those expressed or implied
by such statements. These risks and uncertainties include, without
limitation, the fact that the impacts and expected duration of the
COVID-19 pandemic are uncertain and rapidly changing; the risk that
we may not be able to successfully maintain an effective sales
force to commercialize ZILRETTA; competition from alternative
therapies; the risk that we may not be able to maintain and enforce
our intellectual property, including intellectual property related
to ZILRETTA; the risk that ZILRETTA may not be successfully
commercialized or adopted; risks regarding our ability to obtain
adequate reimbursement from payers for ZILRETTA; risks related to
the manufacture and distribution of ZILRETTA, including our
reliance on sole sources of supply and distribution; risks related
to clinical trials, including potential delays, safety issues or
negative results; risks related to key employees, markets, economic
conditions, health care reform, prices and reimbursement rates; and
other risks and uncertainties described in our filings with the
Securities and Exchange Commission (SEC), including under the
heading “Risk Factors” in our Quarterly Report on Form 10-Q for the
quarter ended June 30, 2020 filed with the SEC on August 5, 2020
and subsequent filings with the SEC. The forward-looking statements
in this press release speak only as of the date of this press
release, and we undertake no obligation to update or revise any of
the statements. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release.
Contact:
Scott YoungVice President, Corporate Communications &
Investor RelationsT: 781-305-7194syoung@flexiontherapeutics.com
Julie DownsAssociate Director, Corporate Communications &
Investor RelationsT: 781-305-7137jdowns@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2023 to Apr 2024